Clinical Trials Browser

Phase 2 × Nasopharyngeal Neoplasms × camrelizumab × Clear all

NCT04978012 2022-06-07

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Phase 2 Unknown

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms